Javier Baigorri

Genetic progress in recent years is only comparable to the advancements in the field of computer science. Our vision is to enable everyone to learn about their unique genetic code and inspire new ideas and scientific approaches. Since the completion of the human genetic code in 2003, the number of studies and sources of information on genetic markers, along with the scientific drive to better understand the genotype-phenotype has grown exponentially. In ADNTRO we help you navigate all present & future findings. Invest in your DNA – its for Life.

Marsi Bionics is recognized as a high impact SME developing disruptive innovative therapies to the healthcare sector. Marsi Bionics’ products are modular gait exoskeletons, ranging from single joint active orthoses to full Trunk-Hip-Knee-Ankle-Foot active orthoses. Our two exoskeletons: ATLAS 2030 paediatric and MAK active knee are unique in the market. Thanks to our innovative ARES joint module, our exoskeletons can adapt to a broader group of patients and diseases, at affordable price.

Genetic progress in recent years is only comparable to the advancements in the field of computer science. Our vision is to enable everyone to learn about their unique genetic code and inspire new ideas and scientific approaches. Since the completion of the human genetic code in 2003, the number of studies and sources of information on genetic markers, along with the scientific drive to better understand the genotype-phenotype has grown exponentially. In ADNTRO we help you navigate all present & future findings. Invest in your DNA – its for Life.

Marsi Bionics is recognized as a high impact SME developing disruptive innovative therapies to the healthcare sector. Marsi Bionics’ products are modular gait exoskeletons, ranging from single joint active orthoses to full Trunk-Hip-Knee-Ankle-Foot active orthoses. Our two exoskeletons: ATLAS 2030 paediatric and MAK active knee are unique in the market. Thanks to our innovative ARES joint module, our exoskeletons can adapt to a broader group of patients and diseases, at affordable price.

At Oliver Wyman, a Marsh business, we bring deep industry insight, bold innovation, and a collaborative approach that cuts through complexity to help organizations navigate their most defining transformative moments. As a business of Marsh, we work alongside the world’s leading experts across risk, reinsurance and capital, people and investments, and management consulting. Together with Marsh Risk, Guy Carpenter, and Mercer, we help organizations build resilience and competitive advantages from every angle. With annual revenue over $24 billion and more than 90,000 colleagues in 130 countries, Marsh helps build the confidence to thrive through the power of perspective